In this regard, a recent investigation by de Souza Rocha et al. [209] has focused on adopting LASSBio-294 as the lead compound to develop a new series of methylated N-acylhydrazones as AR agonists, based on the earlier positive outcomes obtained in the rat model of MI [177,208,210]. This evidence concerns the gene AR and myocardial infarction.